drugset / Trial / NCT06986772
TGRX-678 Pharmacokinetic Mass Balance
Phase 1
Completed
6 enrolled
Shenzhen TargetRx Co., Ltd.
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pharmacokinetic study for \[14C\]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.
Timeline
- Start
- 2025-07-07
- Primary completion
- 2025-08-17
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-678 | Unknown | 240 mg | Oral |